Principal Securities’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$306K Buy
3,906
+28
+0.7% +$1.91K ﹤0.01% 1315
2026
Q1
$251K Buy
3,878
+93
+2% +$6.56K ﹤0.01% 1290
2025
Q4
$255K Buy
3,785
+1,006
+36% +$67.7K ﹤0.01% 1210
2025
Q3
$204K Sell
2,779
-57
-2% -$3.79K ﹤0.01% 1277
2025
Q2
$148K Sell
2,836
-75
-3% -$4.27K ﹤0.01% 1365
2025
Q1
$139K Hold
2,911
﹤0.01% 1286
2024
Q4
$139K Sell
2,911
-89
-3% -$4.56K ﹤0.01% 1284
2024
Q3
$172K Buy
3,000
+1,193
+66% +$68.4K ﹤0.01% 1162
2024
Q2
$94.6K Buy
1,807
+836
+86% +$36.7K ﹤0.01% 1352
2024
Q1
$39.5K Buy
971
+51
+6% +$1.91K ﹤0.01% 1676
2023
Q4
$34K Buy
+920
New +$34.6K ﹤0.01% 1653

Other funds holding HALO

Principal Securities's HALO Position: Q2 2026 in Review

Principal Securities increased its Halozyme (HALO) stake by 0.72% in Q2 2026, buying an estimated $1.91K and bringing the position to 3,906 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Principal Securities first reported a position in HALO in Q4 2023 and has held it in 11 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Principal Securities held 3,906 shares of Halozyme worth $306K as of Q2 2026.
  • Principal Securities bought 28 Halozyme shares in Q2 2026, an estimated $1.91K.
  • Halozyme made up ﹤0.01% of Principal Securities's portfolio in Q2 2026, its #1315 holding.
  • Principal Securities first reported a position in Halozyme in Q4 2023 and has held it in 11 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.